臨床婦人科産科65巻7号

2011年07月発行

今月の臨床 卵巣がん─最新の治療戦略 再発卵巣がん治療

4．セカンドライン化学療法

著者： 松本光史¹

所属機関： ¹兵庫県立がんセンター腫瘍内科

ページ範囲：P.931 - P.938

　本稿では，セカンドライン化学療法のうち，イリノテカン（CPT），リポゾーマルドキソルビシン（PLD），ゲムシタビン（GEM），エトポシド（ETP），トポテカン（TPT）などを用いた化学療法について述べる．OV05／EORTC試験など，いわゆる「マーカー再発」および，ICON4試験などの「セカンドラインにおけるTC療法」については別稿に譲り，本項の主旨に必要な最低限度のみ言及する．

参考文献

1） Nishio S, Katsumata N, Matsumoto K, et al : Usefulness of third-line chemotherapy for women with recurrent ovarian, fallopian tube, and primary peritoneal cancer who receive platinum／taxane regimens as first-line therapy. J Cancer Res clin oncol 135 : 551─557, 2009

2） Hashimoto K, Katsumata N, Hirata T, et al : Po patieuts with Platinum-Resistant epithelial ovarian cancer benefit from second-line chemotherapy? Clin Ovarian Cancer 3 : 36─40, 2010

3） Markman M, Rothman R, Hakes T, et al : Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9 : 389─393, 1991

4） Cantu MG, Buda A, Parma G, et al : Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J Clin Oncol 20 : 1232─1237, 2002

5） Pfisterer J, Plante M, Vergote I, et al : Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer : An intergroup trial of the AGO─OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 24 : 4699─4707, 2006

6） Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al : Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 28 : 3323─3329, 2010

7） Bafaloukos D, Linardou H, Aravantinos G, et al : A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients : A Hellenic Cooperative Oncology Group study. BMC medicine 8 : 3, 2010

8） Schwartz JR, Bandera C, Bradley A, et al : Does the platinum-free interval predict the incidence or severity of hypersensitivity reactions to carboplatin? The experience from Women and Infants’ Hospital. Gynecologic oncology 105 : 81─83, 2007

9） ten Bokkel Huinink W, Gore M, Carmichael J, et al : Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 15 : 2183─2193, 1997

10） Gordon AN, Fleagle JT, Guthrie D, et al : Recurrent epithelial ovarian carcinoma : A randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19 : 3312─3322, 2001

11） Mutch DG, Orlando M, Goss T, et al : Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 25 : 2811─2818, 2007

12） Vergote I, Finkler N, del Campo J, et al : Phase 3 randomised study of canfosfamide（Telcyta, TLK286）versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer. Eur J Cancer 45 : 2324─2332, 2009

13） Ferrandina G, Ludovisi M, Lorusso D, et al : Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol 26 : 890─896, 2008

14） Matsumoto K, Katsumata N, Yamanaka Y, et al : The safety and efficacy of the weekly dosing of irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer. Gynecologic oncology 100 : 412─416, 2006

15） Rose PG, Blessing JA, Mayer AR, et al : Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma : A Gynecologic Oncology Group study. J Clin Oncol 16 : 405─410, 1998

16） Sehouli J, Stengel D, Oskay-Oezcelik G, et al : Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer : Results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol 26 : 3176─3182, 2008

17） Yamanaka YKN, Watanabe T, Andoh M, et al : A dose finding study of irinotecan in combination with oral etoposide in patients with platinum treated advanced epitherial ovarian cancer. Proc Am Soc Clin Oncol 21（abstr 2521）, 2002

18） Nishio S, Sugiyama T, Shouji T, et al : Pilot study evaluating the efficacy and toxicity of irinotecan plus oral etoposide for platinum- and taxane-resistant epithelial ovarian cancer. Gynecologic oncology 106 : 342─347, 2007